# Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

> **NCT00074750** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** DTGM

## Key facts

- **NCT ID:** NCT00074750
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Slow accrual.
- **Last updated:** 2012-02-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074750, "Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00074750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*